# Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

> **NCT04389840** · PHASE2,PHASE3 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)
- Acute Lung Injury
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

## Interventions

- **DRUG:** Dociparstat sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04389840
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-08
- **Primary completion:** 2021-05-20
- **Final completion:** 2021-05-20
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Due to improvement in the Coronavirus Disease 2019 (COVID-19) pandemic and low subject accrual.
- **Last updated:** 2022-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04389840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04389840, "Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04389840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*